Evidence map›Paper›PMID 40623191›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

p63 and ZNF148 cooperate to regulate head and neck squamous cell carcinoma.

Rosalba Pecorari, Mara Mancini, Artem Smirnov, Giacomo Corleone, Flavia Novelli, Anna Maria Lena, Mariacristina Franzese Canonico, Manuela Montanaro, Angela Cappello, Andrea Sacconi and 12 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. WWOX maintains epidermal identity and suppresses EMT to prevent aggressive cutaneous squamous cell carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Rosalba Pecorari *Istituto di Ricovero e Cura a Carattere Scientifico Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Biochemistry Laboratory, Rome 00144, Italy.
Mara Mancini *Istituto di Ricovero e Cura a Carattere Scientifico Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Biochemistry Laboratory, Rome 00144, Italy.ORCID 0000-0001-5173-4854
Artem Smirnov *Istituto di Ricovero e Cura a Carattere Scientifico Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Biochemistry Laboratory, Rome 00144, Italy.ORCID 0000-0002-1575-8725
Giacomo CorleoneStruttura di Area Funzionale di Ricerca Unit (SAFU), Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome 00144, Italy.
Flavia NovelliDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Anna Maria LenaDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.ORCID 0000-0001-6285-9927
Mariacristina Franzese CanonicoDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.ORCID 0009-0003-0096-0503
Manuela MontanaroDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.ORCID 0000-0001-8441-3731
Angela CappelloDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Andrea SacconiBiostatistics, Bioinformatics and Clinical Trial Center, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome 00144, Italy.
Gabriella MissoDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.
Michela FalcoDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.
Chiara TammaroDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.
Fabiola CiccosantiDepartment of Epidemiology, Preclinical Research and Advanced Diagnostics, National Institute for Infectious Diseases Istituto di Ricovero e Cura a Carattere Scientifico "L. Spallanzani", Rome 00149, Italy.ORCID 0000-0003-0481-6878
Mauro PiacentiniDepartment of Epidemiology, Preclinical Research and Advanced Diagnostics, National Institute for Infectious Diseases Istituto di Ricovero e Cura a Carattere Scientifico "L. Spallanzani", Rome 00149, Italy.
Manuel ScimecaDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.
Michele CaragliaDepartment of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy.ORCID 0000-0003-2408-6091
Giovanni BlandinoTranslational Oncology Research Unit, Department of Research, Diagnosis and Innovative Technologies, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome 00144, Italy.
Alessandro MaurielloDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.ORCID 0000-0002-7351-5676
Maurizio FanciulliStruttura di Area Funzionale di Ricerca Unit (SAFU), Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, Istituto di Ricovero e Cura a Carattere Scientifico Regina Elena National Cancer Institute, Rome 00144, Italy.
Gerry MelinoDepartment of Experimental Medicine, University of Rome "Tor Vergata", Rome 00133, Italy.ORCID 0000-0001-9428-5972
Eleonora CandiIstituto di Ricovero e Cura a Carattere Scientifico Istituto Dermopatico dell'Immacolata (IDI-IRCCS), Biochemistry Laboratory, Rome 00144, Italy.ORCID 0000-0001-8332-4825

Funding

Fondazione AIRC per la ricerca sul cancro ETS (AIRC) ID22206Fondazione AIRC per la ricerca sul cancro ETS (AIRC) ID27366Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (AIFA) PNRR-MAD-2022-12375755Italy Ministry of Health | Agenzia Italiana del Farmaco, Ministero della Salute (AIFA) RF-2019-12368888
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is a common and aggressive malignancy. While significant advances have been made in the management of low-grade cancer, treatment of advanced HNSCC remains challenging. Here, we used a proteomic approach to find binding partners of the oncogene p63, the most frequently amplified transcription factor in HNSCC. We identified a zinc finger protein, ZNF148, which is coexpressed and physically binds p63 in carcinoma cells. Genome occupancy analyses identified a functional transcribed enhancer-derived RNA (eRNA) upstream of the CCND1 gene occupied by both factors. Mechanistically, p63 and ZNF148 control transcription of this eRNA, leading to overexpression of cyclin D1 to reinforce tumor cell proliferation. Importantly, this axis is specific for cancer cells and remains inactive in normal epithelial cells. The expression levels of these factors and the eRNA are positively correlated in cancer and associated with advanced stage and metastasis. Collectively, our data reveal a molecular pathway controlling HNSCC progression and identify potential selective targets for cancer treatment.

Indexed as

Carcinoma, Squamous CellDNA-Binding ProteinsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckTranscription FactorsTumor Suppressor ProteinsCell Line, TumorCell ProliferationCyclin D1Gene Expression Regulation, NeoplasticHumansCCND1 protein, humanCyclin D1DNA-Binding ProteinsTP63 protein, humanTranscription FactorsTumor Suppressor ProteinscancerCCND1p63transcriptionZNF148

Identifiers

PMID40623191
PMCPMC12280952

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.